Arrayit Corporation Approved for Direct Medicare Billing by the Centers for Medicare and Medicaid Services
BY ARRAYIT CORPORATION: Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that Arrayit’s proprietary finger stick allergy microarray test has been approved for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS). The Medicare national health insurance program provides health insurance to more than 55 million Americans annually, including 46 million seniors and 9 million younger people. CMS projects a 2018 Medicare budget of approximately $705,000,000,000 ($705 billion dollars), representing about 17% of total federal spending.
Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding FDA approval of a major product line, reported the sale of clinical instrumentation to the FDA, signed allergy testing contracts with a consortium of 178 medical clinics, received approval for in-store promotions by a major retailer, and announced allergy testing partnerships with major allergy therapeutics providers. The new Medicare billing entitlement allows doctors to prescribe Arrayit’s allergy test to a significantly expanded number of patients. (read more)
News 
Market Data 
Discover 
